Quarterly Webinar Series

The AMP-AD Knowledge Portal webinar series, an opportunity to discuss data, analysis, and tools for the study of Alzheimer’s disease generated through the National Institute on Aging’s Translational Research Program. It features speakers from the AMP-AD Target Discovery Program and associated consortia.

Fall 2021

TREAT-AD Webinar | 11.4.2021
The Emory-Sage-SGC TREAT-AD center is taking an open science approach to promoting the study of under-studied AD genes and proteins by providing packages of information and reagents specific to targets to encourage their research as therapeutic AD targets by the research community. Join Drs. Riham Ayoubi and Alison Axtman to discuss strategies and methods for the selection of adequate cell lines for antibody characterization and the assembly and annotation of the AD Informer Set to enable research of targets identified by the AD consortia. Read about the initiative and sign up for the TREAT-AD webinar.


Spring 2021

Conversations with MODEL-AD | Dr. Gregory Carter

The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium discussed their goals, including the development of new models based on recent human genetics, the alignment of AD pathophysiology in mouse models and human studies, the staging of disease progression, and preclinical testing based on translatable biomarkers. View the webinar recording.

Dr. Gregory Carter is an Associate Professor at The Jackson Laboratory, Bar Harbor, ME. He combines genetic, genomic, imaging, and other data resources to understand the causes and progression of Alzheimer’s disease. 


Maria Telpoukhovskaia – Resilience to AD

Maria Telpoukhovskaia of The Jackson Laboratory discusses species-specific differences in mouse and human transcriptomic data sets.


Fall 2020

Dr. Ihab Hajjar on the M2OVE-AD Emory Vascular Study

Dr. Hajjar is a neuroscientist and an Associate Professor of Medicine in the Departments of Neurology and Medicine (Geriatrics). His research is focused on the link between hypertension and vascular disease with brain health including cognitive performance, cerebrovascular function. In particular, he is studying the effects of antihypertensive medications that modulate the renin angiotensin system on both prevention of cognitive decline and as potential therapeutic modalities for early dementia.


Winter 2019

Dying young at an old age: Assembling Proteomics for predicting and protecting against cognitive decline

Dr. Nir Barzilai, Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging.


Fall 2019

Lessons Learned of Mice (and Men): Developing the next generation of AD mouse models

Andrea J. Tenner, PhD is leading the investigation of the role of complement activation and subsequent inflammation in Alzheimer’s disease. Frank A. LaFerla, PhD developed a novel approach to create a triple transgenic model of AD (3xTg-AD) to better model neuropathology.


Summer 2019

ROSMAP: Building the Next-Generation Drug Discovery Pipeline

Dr. David A. Bennett is the director of the Rush Alzheimer’s Disease Center at Rush University Medical Center, Chicago.